These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25673314)

  • 21. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iloprost treatment for refractory Raynaud's phenomenon in two infants.
    Shouval DS; Mukamel M; Zulian F; Amir J; Harel L
    Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S105-7. PubMed ID: 18799065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Raynaud's phenomenon: clinical aspects of the disease].
    Konychev AV; Koreshkina TA; Kokorin KV; Kaiukov AV
    Vestn Khir Im I I Grek; 2001; 160(2):118-22. PubMed ID: 11496483
    [No Abstract]   [Full Text] [Related]  

  • 25. [Iloprost for the treatment of systemic sclerosis].
    Hachulla E; Launay D; Hatron PY
    Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Raynaud's phenomenon, disease or syndrome?].
    Fiessinger JN
    Rev Prat; 2011 Sep; 61(7):899-903. PubMed ID: 22039719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Raynaud's phenomenon in children].
    Quartier P
    Arch Pediatr; 2004 Jan; 11(1):74-7. PubMed ID: 14700771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
    Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
    Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological treatment of Raynaud's phenomenon with special reference to calcium-entry blockers.
    Nilsson H
    Acta Pharmacol Toxicol (Copenh); 1986; 58 Suppl 2():137-49. PubMed ID: 2872769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [An update on the management of Raynaud's phenomenon].
    Rodríguez-García JL
    An Med Interna; 1991 Oct; 8(10):513-20. PubMed ID: 1751694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Iloprost for severe Raynaud's phenomenon and ischaemic ulcers related with systemic diseases].
    García Hernández FJ; Ocaña Medina C; Mateos Romero L; Molinillo López J; Arias Zambrano A; González León R; Sánchez Román J
    Med Clin (Barc); 2004 Apr; 122(13):501-4. PubMed ID: 15104947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Possibilities for clinical use of prostacyclin in vascular disease.
    Poredos P
    Pflugers Arch; 2000; 440(5 Suppl):R137-8. PubMed ID: 11005643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of interventions for secondary Raynaud's phenomenon: a systematic review.
    Huisstede BM; Hoogvliet P; Paulis WD; van Middelkoop M; Hausman M; Coert JH; Koes BW
    Arch Phys Med Rehabil; 2011 Jul; 92(7):1166-80. PubMed ID: 21704799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Calcium antagonists and Raynaud's phenomenon].
    Hachulla E; Devulder B
    Therapie; 1993; 48 Spec No():707-11. PubMed ID: 8091357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue.
    Yardumian DA; Isenberg DA; Rustin M; Belcher G; Snaith ML; Dowd PM; Machin SJ
    Br J Rheumatol; 1988 Jun; 27(3):220-6. PubMed ID: 2454140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Raynaud's phenomenon. An update.
    Coffman JD
    Hypertension; 1991 May; 17(5):593-602. PubMed ID: 2022404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Management of Raynaud's phenomenon].
    Boccalon H; Monin A; Reggy M
    Soins Cardiol; 1986 Apr; (38):27-9. PubMed ID: 3637023
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of alprostadil and iloprost in digital necrosis due to secondary Raynaud's phenomenon.
    Lamprecht P; Schnabel A; Gross WL
    Br J Rheumatol; 1998 Jun; 37(6):703-4. PubMed ID: 9667634
    [No Abstract]   [Full Text] [Related]  

  • 39. Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon.
    Watson HR; Belcher G
    Ann Rheum Dis; 1991 Jun; 50(6):359-61. PubMed ID: 1711834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon.
    Kyle MV; Belcher G; Hazleman BL
    J Rheumatol; 1992 Sep; 19(9):1403-6. PubMed ID: 1279169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.